Catalyst Pharmaceuticals, Inc.
$31.49$0.00 (0.0%)
Last close · Data as of Jul 21, 2026
- Market cap
- $3.8B
- P/E
- 17.9x
- EV / EBITDA
- 10.6x
- Revenue
- $589.0M
- Net margin
- 36.4%
- ROCE
- 26.9%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 21 Jul 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change $0.00 (0.0%) from $31 to $31 · Last close Jul 21, 2026
Best weekday to invest, historically
The same weekly amount in CPRX, bought on each weekday since 2021.
News & filings
What Catalyst Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating margin of 43.8% against a peer median of 12.7%.
Concerns
No concern stands out for this company on the data on file.
- Prices are as of 21 Jul 2026; price-based points are paused until newer prices arrive.
Prices to the 21 Jul 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
Read moreShow less
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
- Sector
- Healthcare
- Shares outstanding
- 122.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $3.8B
- P/E
- 17.9x
- P/B
- 4.0x
- EV / EBITDA
- 10.6x
- EV / Sales
- 5.3x
- P/S
- 6.5x
- 52-week high
- $31.50
- 52-week low
- $19.13
Profitability
- Operating margin
- 43.8%
- Net margin
- 36.4%
- EBITDA margin
- 50.2%
- ROE
- 22.5%
- ROCE
- 26.9%
- ROA
- 19.4%
- Asset turnover
- 0.53
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $589.0M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 19.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 40.1%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 30.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $208.6M
Solvency
- Current ratio
- 6.08
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- 0.97
- Cash / Market cap
- 18.5%
Where the revenue went
Of every $100 of FY2025 revenue, $36 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $87.3M |
| Revenue | Gross profit | $501.7M |
| Gross profit | Research and development | $12.7M |
| Gross profit | Selling, general and administrative | $193.8M |
| Gross profit | Other operating expenses | $37.5M |
| Gross profit | Operating income | $257.8M |
| Operating income | Pretax income | $257.8M |
| Interest and other income | Pretax income | $25.7M |
| Pretax income | Tax and other | $69.2M |
| Pretax income | Net income | $214.3M |
Revenue and net profit
Revenue grew 19.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $214.2M | $83.1M |
| FY2023 | $398.2M | $71.4M |
| FY2024 | $491.7M | $163.9M |
| FY2025 | $589.0M | $214.3M |
Cash flows
FY2025: $208.7M from operations, $208.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $116.0M | $116.0M |
| FY2023 | $143.6M | $61.9M |
| FY2024 | $239.8M | $239.3M |
| FY2025 | $208.7M | $208.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $589.0M+19.8%1Y
- EBITDA
- $295.7M+26.9%1Y
- Net profit
- $214.3M+30.8%1Y
- Cash from operations
- $208.7M-13.0%1Y
- Free cash flow
- $208.6M-12.8%1Y
- Revenue CAGR, 3Y
- 40.1%
- Net profit CAGR, 3Y
- 37.1%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $589.0M | $295.7M | $214.3M | $208.6M | 22.5% | +19.8% | +30.8% |
Monthly returns
Month-by-month returns of CPRX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.1B |
| Current assets | $894.0M |
| Non-current assets | $209.9M |
| Liabilities | $149.7M |
| Current liabilities | $147.2M |
| Non-current liabilities | $2.6M |
| Equity | $954.3M |
| Paid-in capital | $480.0M |
| Retained earnings | $474.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CPRX highlighted.
P/E against peers
CPRX trades at 17.9x earnings against a peer median of 31.9x (a 44% discount).
Not shown (no positive earnings and no EV / Sales): RadNet, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Catalyst Pharmaceuticals, Inc.CPRXthis companyP/E ↓ discount | $3.8B | 17.9x | 4.0x | 22.5% | 10.6x |
| Amneal Pharmaceuticals, Inc.AMRX | $4.3B | 59.9x | -60.9x | -101.8% | 11.1x |
| RadNet, Inc.RDNT | $4.2B | -222.6x | 3.8x | -1.7% | 16.7x |
| Veracyte, Inc.VCYT | $4.0B | 60.1x | 3.0x | 5.1% | 40.9x |
| Waystar Holding Corp.WAY | $3.9B | 34.6x | 1.0x | 2.9% | 13.6x |
| Merit Medical Systems, Inc.MMSI | $3.8B | 29.3x | 2.4x | 8.1% | 12.5x |
| ACADIA Pharmaceuticals Inc.ACAD | $3.7B | 9.5x | 3.0x | 31.9% | 30.8x |
| Organon & Co.OGN | $3.5B | 18.8x | 4.7x | 24.9% | 9.0x |
| ICU Medical, Inc.ICUI | $3.4B | 4607.1x | 1.6x | 0.0% | 14.7x |
| Peer median | — | 31.9x | 2.7x | 4.0% | 14.1x |
Year-to-date ROI
CPRX since 1 January, against earlier years.
Historical volatility
CPRX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 47.5% |
| FY2023 | 21.8% |
| FY2024 | 39.7% |
| FY2025 | 43.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $589.0M |
| Cost of revenueCost Of Revenue | $87.3M |
| Gross profitGross Profit | $501.7M |
| Operating expensesOperating Expense | $244.0M |
| Research and developmentResearch And Development | $12.7M |
| Selling, general and administrativeSelling General And Administration | $193.8M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $37.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $37.5M |
| Amortization | $37.5M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $37.5M |
| Total expensesTotal Expenses | $331.2M |
| Operating incomeOperating Income | $257.8M |
| Interest and other | |
| Pretax incomePretax Income | $283.5M |
| TaxTax Provision | $69.2M |
| Net incomeNet Income | $214.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.1B |
| Current assetsCurrent Assets | $894.0M |
| Non-current assetsTotal Non Current Assets | $209.9M |
| LiabilitiesTotal Liabilities Net Minority Interest | $149.7M |
| Current liabilitiesCurrent Liabilities | $147.2M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $2.6M |
| EquityTotal Equity Gross Minority Interest | $954.3M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $208.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $208.7M |
| Net income, continuing operationsNet Income From Continuing Operations | $214.3M |
| Depreciation and amortisationDepreciation And Amortization | $37.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $37.9M |
| Depreciation | $380.0k |
| Amortization cash flowAmortization Cash Flow | $37.5M |
| Amortization of intangiblesAmortization Of Intangibles | $37.5M |
| Stock-based compensationStock Based Compensation | $24.8M |
| Deferred taxDeferred Tax | -$6.8M |
| Deferred income taxDeferred Income Tax | -$6.8M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | -$970.0k |
| Asset impairmentAsset Impairment Charge | $460.0k |
| Change in working capitalChange In Working Capital | -$60.9M |
| Other non-cash itemsOther Non Cash Items | -$60.0k |
| Investing cash flowInvesting Cash Flow | -$60.0k |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$60.0k |
| Capital expenditureCapital Expenditure | -$60.0k |
| Purchase of PP&EPurchase Of PPE | -$60.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$60.0k |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | $0.00 |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | $0.00 |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | -$17.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$17.0M |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | -$25.3M |
| Common stock repurchasedCommon Stock Payments | -$25.3M |
| Share buybacksRepurchase Of Capital Stock | -$25.3M |
| Stock options exercisedProceeds From Stock Option Exercised | $14.7M |
| Other financing chargesNet Other Financing Charges | -$6.4M |
| Change in cashChanges In Cash | $191.6M |
| Cash at the start of the yearBeginning Cash Position | $517.5M |
| Cash at the end of the yearEnd Cash Position | $709.2M |
| Free cash flowFree Cash Flow | $208.6M |
| Supplemental |
Learn while you research
Academy chapters picked for Catalyst Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read